News from phaserx, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 13, 2017, 06:05 ET PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Dec 11, 2017, 06:05 ET PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Nov 28, 2017, 07:30 ET PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Nov 09, 2017, 07:00 ET PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Oct 31, 2017, 08:00 ET PhaseRx to Present at 5th International mRNA Conference

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Oct 26, 2017, 18:30 ET PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Oct 13, 2017, 08:30 ET PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Sep 20, 2017, 14:07 ET PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Aug 10, 2017, 08:30 ET PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

May 12, 2017, 08:30 ET PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

May 03, 2017, 08:30 ET PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Apr 27, 2017, 16:05 ET PhaseRx to Present Data at the TIDES Conference

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Apr 25, 2017, 08:30 ET PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Mar 27, 2017, 08:30 ET PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Feb 27, 2017, 07:30 ET PhaseRx to Present at Upcoming Investor Conferences

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children,...

Feb 08, 2017, 07:00 ET PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium™ 2017

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Jan 04, 2017, 08:30 ET PhaseRx to Present at Biotech Showcase 2017

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Nov 28, 2016, 08:30 ET PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today ...

Nov 08, 2016, 08:30 ET PhaseRx Announces Positive Safety Results from Large Animal Study with Hybrid mRNA Delivery Technology

PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE

News from phaserx, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 13, 2017, 06:05 ET PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares

Dec 11, 2017, 06:05 ET PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding

Nov 28, 2017, 07:30 ET PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency

Nov 09, 2017, 07:00 ET PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Oct 31, 2017, 08:00 ET PhaseRx to Present at 5th International mRNA Conference

Oct 26, 2017, 18:30 ET PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options

Oct 13, 2017, 08:30 ET PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives

Sep 20, 2017, 14:07 ET PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency

Aug 10, 2017, 08:30 ET PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update

May 12, 2017, 08:30 ET PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update

May 03, 2017, 08:30 ET PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting

Apr 27, 2017, 16:05 ET PhaseRx to Present Data at the TIDES Conference

Apr 25, 2017, 08:30 ET PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency

Mar 27, 2017, 08:30 ET PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

Feb 27, 2017, 07:30 ET PhaseRx to Present at Upcoming Investor Conferences

Feb 08, 2017, 07:00 ET PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium™ 2017

Jan 04, 2017, 08:30 ET PhaseRx to Present at Biotech Showcase 2017

Nov 28, 2016, 08:30 ET PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency

Nov 08, 2016, 08:30 ET PhaseRx Announces Positive Safety Results from Large Animal Study with Hybrid mRNA Delivery Technology

Nov 07, 2016, 08:30 ET PhaseRx Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Oct 25, 2016, 08:30 ET PhaseRx to Present at 2016 International mRNA Health Conference

Oct 11, 2016, 08:30 ET PhaseRx to Present Company Overview at Upcoming Investor Conferences

Sep 14, 2016, 08:30 ET PhaseRx to Present at the 2016 Aegis Growth Conference

Aug 22, 2016, 04:05 ET PhaseRx Appoints Peggy Phillips to Board of Directors

Aug 02, 2016, 04:05 ET PhaseRx Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Journalists and Bloggers

The news you need, when you need it.

Contact Cision

Products

About

My Services